Phase 1/2 Study of Liposomal Annamycin in Combination with Cytarabine for the Treatment of Subjects with Acute Myeloid Leukemia (AML).

Status

Completed

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-516388-10-00

Acronym

MB-106

Enrollment

Registered

2024-08-26

Start date

2022-09-23

Completion date

2025-08-26

Last updated

2025-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Myeloid Leukemia

Brief summary

CR: a. achievement of normal bone marrow morphology on light microscopy with fewer than 5% blasts b. recovery of peripheral blood counts with an absolute neutrophil count >1.0 × 109/L and platelet counts >100 × 109/L, CRi: CR with incomplete recovery of platelets and/or neutrophils, PR: a ≥50% decrease in marrow blasts, Subject deemed eligible for hematopoietic stem cell transplantation

Interventions

DRUGALEXAN

DRUG50 MG/ML

DRUGROZTWÓR DO INFUZJI

DRUGLiposomal Annamycin

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
CR: a. achievement of normal bone marrow morphology on light microscopy with fewer than 5% blasts b. recovery of peripheral blood counts with an absolute neutrophil count >1.0 × 109/L and platelet counts >100 × 109/L, CRi: CR with incomplete recovery of platelets and/or neutrophils, PR: a ≥50% decrease in marrow blasts, Subject deemed eligible for hematopoietic stem cell transplantation	—

Countries

Italy, Poland

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026